(12-045) Adjustments in Insulin Dosing After Initiation of a Glucagon-like Peptide-1 Receptor Antagonist(GLP-1 RA) or Combination GLP-1 RA/Glucose-dependent insulinotropic polypeptide(GIP) in Patients with Type 2 Diabetes
Wednesday, December 10, 2025
2:00 PM - 3:00 PM
Location: Bayside A, Level 1
Residency Program: MH Mission Hospital, LLLP Residency Program Type: PGY1 (Pharmacy) Residency Program Location: North Carolina
